GEA Group (G1A) Q3 2025 earnings summary

Executive summary

• Achieved DAX 40 index entry, marking a milestone as one of Germany's top listed companies.

• Order intake grew 5.5% to €1,372.4M (organic: 8.4%), with strong demand in Pharma, Food, and Dairy Farming.

• Major organizational restructuring underway, reducing the executive board and targeting cost savings of €10–15m in 2026 and €20–25m in 2027.

• 94% of managers support the organizational changes.

• Continued focus on sustainability and ESG, with increased ESG investor interest.

Financial highlights

• Q3 order intake rose 5.5% year-over-year to €1,372m, with sales up 1.2% to €1,366m; organic sales growth was 4.5%.

• EBITDA before restructuring expenses increased 6.7% to €232m, margin reached a record 17.0%.

• ROCE rose to 35.4% (Q3 2024: 32.3%).

• Net liquidity declined to a net debt position of €36.3m, mainly due to share buybacks.

• Free cash flow for Q3 was €52m; cash conversion ratio over the last four quarters was 47%.

Outlook and guidance

• Fiscal 2025 guidance confirmed: organic sales/revenue growth of 2.0–4.0%, EBITDA margin before restructuring expenses of 16.2–16.4%, and ROCE of 34–38%.

• Expectation of strong Q4 order intake, including large orders like Balatna.

• Management confident in achieving Mission 30 targets, with 2026 expected to see accelerated organic sales growth and margin improvement.

• No changes expected for individual divisions; IMF forecasts global GDP growth of 3.2% for 2025.